Assessing Clinical Research Barriers to the Participation of Underrepresented Groups in the AHEAD Study
Taryn T. James, Carey E. Gleason, Diane Carol Gooding, Fabu P. Carter, Cecilia A. Cardenas, Olivia Deering, Aleshia Cole, Kate Cronin, Cynthia M. Carlsson, Shenikqua Bouges · 2025
Read Assessing Clinical Research Barriers to the Participation of Underrepresented Groups in the AHEAD Study by Taryn T. James, Carey E. Gleason, Diane Carol Gooding, Fabu P. Carter, Cecilia A. Cardenas, Olivia Deering, Aleshia Cole, Kate Cronin, Cynthia M. Carlsson, Shenikqua Bouges (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715507.txt.
Description
Alzheimer's trials keep enrolling too few people from the groups the disease hits hardest, and one team went to the community to ask why. Taryn T James and co-authors report the outreach in a 2025 paper. Their target was the AHEAD study, testing a drug in people with silent early disease. A diversity grant funded surveys of what potential participants knew and feared. Questions covered the drug, the study, and comfort with taking part.
Most respondents had never heard of the drug or the study, the team found. Survey takers received a small gift bag for their time. Results feed a plan to lower the named barriers. Applicable therapies need representative trials, the authors argue.
Catalog record
| CREATOR | Taryn T. James, Carey E. Gleason, Diane Carol Gooding, Fabu P. Carter, Cecilia A. Cardenas, Olivia Deering, Aleshia Cole, Kate Cronin, Cynthia M. Carlsson, Shenikqua Bouges |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |